Evoke Pharma (NASDAQ:EVOK) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note released on Thursday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Shares of EVOK stock opened at $2.82 on Thursday. The company’s fifty day moving average price is $4.40 and its 200-day moving average price is $4.67. Evoke Pharma has a one year low of $2.50 and a one year high of $12.32. The company has a market capitalization of $4.21 million, a price-to-earnings ratio of -0.26 and a beta of 0.12.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%. The firm had revenue of $3.31 million during the quarter, compared to analysts’ expectations of $3.08 million.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Evoke Pharma stock. Nantahala Capital Management LLC boosted its stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 148,194 shares of the specialty pharmaceutical company’s stock after purchasing an additional 91,945 shares during the period. Nantahala Capital Management LLC owned approximately 9.95% of Evoke Pharma worth $655,000 at the end of the most recent reporting period.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.